VANCOUVER and TORONTO, Canada — Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, is pleased to announce that Mr. Luc Mainville has been appointed Chair of its Board of Directors.
Mr. Mainville is the President and Founder of LUMA Capital and LUMA Life, previously serving as Executive Vice President of Cardiome Pharma Corp., and President and Chief Executive Officer of Neopharm Labs Inc. and LAB Research Inc. He brings considerable experience throughout his career in which he has served in senior corporate, and director roles for a number of public and private companies in the biotechnology and pharmaceutical industries. In particular, Mr. Mainville has led more than 30 mergers and acquisitions, as well as served as Chair of the Board of Alethia BioTherapeutics, Bioaxone Therapeutics, and Powertech Corporation as well as Chair of the Audit Committee for a number of Boards, including that of Acerus Pharma, Enobia Pharma, and Cyplasin Biomedical. He served as Vice-Chairman of BioteCanada, and also teaches corporate governance and mergers and acquisitions courses at McGill University in Montreal, Quebec. Prior to his career in the life science industry, he was a Partner at KPMG.
Michael Midmer, Chief Executive Officer of Zucara remarked, “We are pleased to welcome Luc Mainville as Chair of our Board of Directors. Mr. Mainville brings a strong track-record in building and financing companies and moving preclinical technologies to the clinical trial stage and beyond. He will provide a complementary background to a well-rounded Board dedicated to advancing Zucara’s lead drug toward the clinic, and ultimately to improving the lives of diabetes patients worldwide.”
– 30 –
About Zucara Therapeutics Inc.
Zucara Therapeutics, a spin-off of The Centre for Drug Research and Development (CDRD) and MaRS Innovation (MI), is developing the first drug therapy to prevent hypoglycemia in people with diabetes. The Company’s first-in-class therapeutic is aimed at inhibiting a hormone in the pancreas called somatostatin, which does not function properly in Type 1 diabetes. Preventing hypoglycemia will dramatically change diabetes disease management, improving both patient health and quality of life. www.zucara.ca
For additional information, please contact:
Senior Manager, Communications